The prospect of changing the plasticity of terminally differentiated cells toward pluripotency has completely altered the outlook for biomedical research. Human-induced pluripotent stem cells (iPSCs) provide a new source of therapeutic cells free from the ethical issues or immune barriers of human embryonic stem cells. iPSCs also confer considerable advantages over conventional methods of studying human diseases. Since its advent, iPSC technology has expanded with 3 major applications: disease modeling, regenerative therapy, and drug discovery. Here we discuss, in a comprehensive manner, the recent advances in iPSC technology in relation to basic, clinical, and population health. (J Am Coll Cardiol 2016;67:2161-76) 
S ince the initial discovery that bone marrow cells possess regenerative capacity through clonal expansion, which laid the foundation for the field (1), regenerative medicine has come a long way. As a type of stem cell, these bone marrow cells have the capacity for both self-renewal and differentiation into different cell types. Earlier attempts to understand the pluripotency of the inner cell mass focused on the developmental capacity of nuclei by cloning in frogs (2), cloning in adult mammalian cells (3), derivation of mouse and human embryonic stem cells (ESCs) (4,5), and generation of ESCs and somatic cell fusion (6). Similarly, MyoD, a mammalian transcription factor, was found capable of converting fibroblasts to myocytes, which led to the concept of master regulators, transcription factors that determine lineage specification (7). Using these paradigms, (15, 16) , use of vectors that can be excised from the genome (17, 18) , use of "nonintegrating" vectors (19, 20) , supplementation of reprogramming factors with microribonucleic acids (21) , use of recombinant proteins/ peptides to reprogram somatic cells (22, 23) , and most recently, a purely chemical approach (24) .
With the concerted efforts of the academic community, the past decade has seen a tremendous push toward the efficient generation of safer PSCs, with the hope that one day iPSCs could be used for regenerative medicine in the clinic (25) . Although halted temporarily, the clinical trial using iPSC-derived retinal pigment epithelial cells (iPSC-RPEs) for treatment of macular degeneration shows how far we have come in developing clinical-grade stem cells (26) . In the short run, iPSC technology will likely offer more avenues to understand the pathophysiology of diseases and discover new therapeutic molecules. Specifically, for disease modeling, iPSCs can be generated from patients who carry certain genetic mutations and then differentiated into disease-relevant cell types, such as cardiomyocytes (iPSC-CMs) (27) (28) (29) .
Similarly, iPSC-derived cells can then be subjected to high-throughput screens to discover new therapeutic small molecules or conduct drug toxicity assays.
Lastly, iPSC technology might enable personalized therapies (i.e., cell or tissue replacement without the need for immunosuppression, and use of drugs tailored according to each patient's genes, environment, and life-style). This is precision medicine, an initiative with the intent to cure each patient by taking into account his or her unique genetic makeup (30) . The goal is to understand the complex mechanism of diseases so that made-to-order treatment plans could be designed for each patient based on their condition. In this review paper, we aim to highlight the promise of iPSCs for expanding basic science research and generating novel therapeutic agents for clinical and public health applications.
iPSC TECHNOLOGY: EMERGING CONCEPTS
The greatest hallmark of iPSC technology lies in its simplicity and reproducibility. Although the past decade has shown great improvement in making iPSCs safer and more efficacious, which is critical for pushing the technology toward clinical application, the mechanisms involved in efficient generation of iPSCs are just emerging. These evolving concepts raise important fundamental questions that will be discussed in the following sections.
HOW CAN A FEW TRANSCRIPTION FACTORS TURN
BACK THE CELLULAR CLOCK? Many studies have tried to address this question, but the general consensus is that the initial activity of the core pluripotency genes (OSKM) has a snowball effect that results in simultaneous activation of the entire endogenous network of pluripotency genes and inhibition of lineage-specific genes within the reprogrammed somatic cells. The initial phase of reprogramming is associated with cells undergoing metabolic changes and genome-wide alterations in histone marks and methylation, followed by a late maturation phase that causes defined changes in nuclear structure, the cytoskeleton, and signaling pathways (31,32). Indeed, by looking closely at these mechanisms, researchers can now obtain nearly perfect iPSCs by clearing previous roadblocks to reprogramming (33) . ARE THESE iPSCs THE SAME AS ESCs? An important question that comes up repeatedly is whether iPSCs have the same genetic and epigenetic landscape as ESCs, and whether differentiated cells (e.g., CMs) from these 2 types of stem cells behave similarly.
Despite several previous studies suggesting differences in gene expression or deoxyribonucleic acid (DNA) methylation between iPSCs and ESCs (34) (35) (36) , the majority of iPSC and ESC clones are largely indistinguishable (37) (38) (39) . More recent reports suggest that both cell types have identical molecular and functional characteristics, with variations in their genetic backgrounds (i.e., different donors for iPSCs and ESCs) accounting for most of their regulatory differences (40) . Human iPSCs for Precision Medicine M A Y 1 0 , 2 0 1 6 : 2 1 6 1 -7 6 COULD TRANSDIFFERENTIATION BE THE NEXT STEP? Another emerging concept is the direct reprogramming of one somatic cell type to another desired cell type as an alternative approach to iPSCs.
Termed transdifferentiation, this concept relies on the premise that we could achieve rapid reprogramming of a desired cell type by entirely avoiding the iPSC stage (41) . Several groups have shown successful transdifferentiation of fibroblasts to various types of somatic cells, such as neurons (42), hepatocytes (43) , CMs (44) , and endothelial cells (45, 46) . However, a current major drawback to the use of direct reprogramming for clinical purposes is the tremendous difficulty of obtaining sufficient numbers of target cells that fully recapitulate the properties of the desired cells (47) . In addition, transdifferentiation has thus far failed to generate a pure population of desired cells, which makes it difficult for them to be used for disease modeling and drug development (48) . Similarly, in contrast to iPSCs, which once reprogrammed can be easily maintained and differentiated to a desired cell type, the transdifferentiation approach would require restarting the entire reprogramming process for each experiment.
APPLICATIONS OF iPSCs
There are many human diseases that have limited treatment options because of either a lack of relevant tissue samples or a lack of information regarding disease progression. Thus, researchers traditionally have relied on in vitro assays or animal models to understand disease progression and develop therapeutic interventions. These model systems use either small animals (e.g., rats and mice) or large animals (e.g., dogs, pigs, and nonhuman primates). These research designs are premised on the ability of the animal model to mimic human subjects pathophysiologically and to eventually develop end-stage disease like that seen in humans. However, because of differences in cardiovascular anatomy and physiology (e.g., humans and rodents diverged w75 million years ago), animal models often do not accurately reproduce human pathophysiology in meaningful ways. Because iPSCs can be derived from healthy and diseased patients, they can be a robust alternative to animals for modeling human diseases ( Figure 1) .
Indeed, several models of iPSCs have been generated and explored for studying various human diseases, as outlined in the next section. DISEASE MODELING. The inherent properties of iPSCs for self-renewal and differentiation into any cell type make them an ideal candidate for modeling human diseases. Because many of the genetic variants that distinguish affected patients from unaffected subjects are located in noncoding regions of the human genome with limited alignment to genomes of animals used as model systems, we run the risk that even after introducing the same human genetic variant in the animal model, we might fail to recapitulate the human disease phenotype (49) . Thus, there is a compelling need to model human diseases using human samples. Since the groundbreaking creation of the first human iPSCs (9), many groups have applied this technology to model human diseases, with amyotrophic lateral sclerosis and various congenital diseases among the first to be modeled using patient-specific iPSCs (12,50,51). Since these reports, many have attempted to study human diseases using iPSCs from patients with neurodegenerative diseases (50, 52) , cardiovascular disorders (53) (54) (55) (56) , muscular dystrophies (57, 58) , and hematologic disorders (59, 60) , to name a few. Cardiovascular diseases that have been studied are summarized in Table 1 . Disease modeling using iPSC-CMs has been feasible because of ever-improving differentiation protocols (27, 29, 90) . Importantly, although the phenotypic characteristics of the iPSC-CMs are similar to those of primary human CMs with respect to their molecular, electrophysiological, mechanical, and metabolic properties, these functional characteristics also indicate that they resemble fetal rather than adult CMs. Structurally, compared with adult human CMs, these iPSC-CMs look much smaller in size and have less sarcomeric organization with decreased force generation (91) (92) (93) . This could diminish their utility for modeling adult-related heart diseases. Table 2 summarizes the differences between immature and mature CMs. Disease-specific target cells differentiated from patient-specific induced pluripotent stem cells (iPSCs) have 3 major applications: disease modeling, regenerative therapies, and drug discovery/toxicity studies. iPSCs from patients with genetic mutations could be corrected via genome editing to yield healthy target cells for cell therapy. Both corrected and uncorrected target cells could be used for disease modeling or drug screening. RBC ¼ red blood cells.
Sayed et al. Human iPSCs for Precision Medicine their structure and function, much research now focuses on uncovering factors and pathways that drive their maturation (120) . Agents and cues that have been explored to induce maturation include micro-RNAs (121, 122) , chromatin and histone proteins (123), DNA methylation (124), metabolic energetics (125) , and biochemical cues (126, 127) . By decoding these signaling pathways, substantial progress has been made in generating more mature iPSC-CMs. Additional future studies using high-throughput experiments would be necessary to unravel the complexity of full cardiac maturation. Unraveling these pathways could potentially allow us to bring iPSC-CMs to maturity in a dish, with closer resemblance to the adult human heart. However, it is unlikely that cells grown under in vitro conditions will fully resemble cells residing in intact living subjects because of differences in environmental milieu, whether cardiac or noncardiac. Hence, the expectation that iPSC-CMs will be identical to mature primary human CMs might be unrealistic. Endogenous cellular mechanisms then repair these breaks by homologous recombination (129) . With these tools, it is now possible to generate human cellular disease models in a precise and predictable manner. Indeed, genome editing has been used to introduce genetic alterations to create cardiac disease models or correct genetic mutations in iPSC-CMs to model cardiac diseases. Single genetic mutations responsible for cardiomyopathies, such as dilated cardiomyopathy, Barth syndrome, long-QT syndrome, and Duchenne muscular dystrophy, have been corrected by use of these genome-editing tools (68, 70, 71, 130, 131) , which suggests the feasibility of this approach for disease modeling. However, these engineered nucleases could introduce unintended genomic alterations; for example, in addition to cleaving the on-target site, they might have off-target effects. Similarly, other challenges, such as delivery methods and efficiency, still need to be sorted out (132) . Taken together, this tag-team technology of patient-specific iPSCs and genome editing could lay the groundwork required to achieve the bold initiative of precision health (30) . REGENERATIVE MEDICINE. The use of PSCs, such as ESCs and iPSCs, for cell transplantation or organogenesis has captured the imagination of the lay public, but it remains a difficult task to achieve from a scientific standpoint. The limitations of organ transplantation, which is plagued by lack of organ availability and problems with immunorejection, have led Similarly, iPSCs generated from patients with retinitis pigmentosa, a condition that involves retinal degeneration, were able to differentiate to rod photoreceptor cells and have beneficial effects (136, 137) . Human iPSCs for Precision Medicine cells, retain them in situ, and use them to replace scar tissue with a large number of stem cell derivatives. In addition to being a vehicle for cell delivery, cardiac patches have been shown to stimulate endogenous paracrine factors that assist in cardiac repair (156, 157) .
Although there is much enthusiasm for the use of CMs to a selection of known drugs that affect the hERG channel have shown comparable data to conventional hERG by use of in vitro assays (165, 166) .
These studies indicate that PSC-CMs could be adopted as a standard model for cardiotoxicity studies.
Importantly for pharmaceutical companies, this model could be a suitable addition to their conventional drug screening methods.
iPSC-based drug screening: precise and personal. Every patient has a unique genetic background and reacts differently to medications. Despite presenting with Human iPSCs for Precision Medicine M A Y 1 0 , 2 0 1 6 : 2 1 6 1 -7 6 similar symptoms, patients might have different underlying causes of the disease, but conventionally, they will still receive the same medication on the basis of their symptoms. iPSC-based drug screening technology might allow evaluation of a personalized therapy for every patient, an approach known as precision medicine (30) .
With the advent of iPSCs (9) and the improvements in differentiating iPSCs to functional CMs (27, 29, 90) , This cellular immaturity issue might seriously limit The conventional drug discovery pathway is a very inefficient process with a high attrition rate. The majority of candidate drugs never reach the market because of safety and efficacy issues. This is attributable in part to the lack of appropriate drug development models that could accurately predict drug efficacy and in part to dependence on animal models of disease that do not replicate human pathophysiology. (B) By comparison, induced pluripotent stem cell (iPSC) technology allows highthroughput screening of therapeutic molecules by providing disease-specific drug development models that are generated from the patients themselves. This makes iPSC technology a much better predictive tool and enables well informed decisions to be made earlier in the drug development process. FDA ¼ U.S. Food and Drug Administration; iPSC-CM ¼ induced pluripotent stem cell-derived cardiomyocyte. contractile apparatus (120, 168) . Others have tried to achieve maturity by overexpressing microRNAs (miR-1/miR-499, Let7) to improve metabolic energetics (121, 125) or by subjecting the cells to electrical and mechanical stimulation (169) . In addition, uniaxial stretching of engineered heart muscle made from PSC-CMs could enhance their viability and maturation and has been used for drug screening (170) . Despite their resemblance to fetal CMs and their labeling as "immature" CMs, these PSC-CMs have been used successfully to study drug efficacy and toxicity (84, 85) . Rather than a generalized approach, the diagnostic and therapeutic strategies are now patient oriented, with a focus on precision medicine (30) . This involves integrating the patient's "omics" information (e.g., There have been more than 700 publications in the past few years that have expanded their use to additional human diseases (both monogenic and polygenic). These advances in cardiac disease modeling have been made possible because of tissue-specific differentiation protocols that allowed researchers to derive healthy and disease-specific CMs ( Table 1 ). In addition to disease modeling, several groups have tried to inject PSC-CMs into small and large animal models of myocardial infarction, with varying levels of success. Concerted efforts are now under way to further enhance the pre-clinical outcome of these PSC-CMs when transplanted into animal models of cardiac diseases. PSC-CMs also provide a unique platform to conduct drug-screening assays and to discover novel therapeutics. However, a major concern thus far is the immature status of the PSC-CMs. Various approaches, including cardiac tissue bioengineering, have been utilized to bring these PSC-CMs to maturity. Finally, the availability of genetically affected human tissues is very limited.
Genome-edited PSC lines have now made it possible to recapitulate the human disease in a dish by use of various gene-editing tools, such as endonucleases (zinc finger nucleases or transcription activator-like effector nuclease) or palindromic repeats (clustered regularly-interspaced short palindromic repeat).
Libraries of disease-specific cells can now be generated by creating allele-specific patient iPSC lines with which to conduct drug testing and toxicity studies. In summary, iPSC technology is not only revolutionizing science but will also fundamentally alter our healthcare system and the future of medicine by making it proactive, predictive, preventive, and personalized. 
